Sylvant

Active Ingredient(s): Siltuximab
FDA Approved: * April 22, 2014
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Sylvant Overview

Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6.[1][2] Siltuximab has been investigated for the treatment of neoplastic diseases:[3] metastatic renal cell cancer,[4] prostate cancer,[5] and Castleman's disease,[6][7] among ot...

Read more Sylvant Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Siltuximab

Recent Sylvant Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Siltuximab

Injection: 100mg, 400mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Sylvant: (2 results)

Sorted by National Drug Code

57894-420 Sylvant 100 mg Intravenous Injection, Powder, Lyophilized, for Solution by Janssen Biotech, Inc.
57894-421 Sylvant 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by Janssen Biotech, Inc.

Other drugs which contain Siltuximab or a similar ingredient: (1 result)

SILTUXIMAB